Immuno-PET Imaging to Assess Target Engagement: Experience from ⁸⁹Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors.

ABSTRACT: PET imaging with radiolabeled drugs provides information on tumor uptake and dose-dependent target interaction to support selection of an optimal dose for future efficacy testing. In this immuno-PET study of the anti-human epidermal growth factor receptor (HER3) mAb GSK2849330, we investigated the biodistribution and tumor uptake of ⁸⁹Zr-labeled GSK2849330 and evaluated target engagement as a function of antibody mass dose. Methods:⁸⁹Zr-GSK2849330 distribution was monitored in 6 patients with HER3-positive tumors not amenable to standard treatment. Patients received 2 administrations of ⁸⁹Zr-GSK2849330. Imaging after tracer only was performed at baseline; dose-dependent inhibition of ⁸⁹Zr-GSK2849330 uptake in tumor tissues was evaluated 2

SUBMITTER: Menke-van der Houven van Oordt CW 

PROVIDER: S-EPMC6604691 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature